apc conjugated cxcr4 antibody (Miltenyi Biotec)
Miltenyi Biotec is a verified supplier 
Miltenyi Biotec manufactures this product 
Structured Review
Apc Conjugated Cxcr4 Antibody, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 93/100, based on 8 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/actin+polymerization+depolymerization+kit/CD184+(CXCR4)+MicroBead+Kit%2C+human/pm39992057-186-21-25
Average 93 stars, based on 8 article reviews
Images
1) Product Images from "CXCR4 confers stemness and radioresistance in chordoma cells."
Article Title: CXCR4 confers stemness and radioresistance in chordoma cells.
Journal: Cancer biology & therapy
doi: 10.1080/15384047.2025.2471631
Figure Legend Snippet: Figure 1. CXCR4+ DTC cells exhibit enhanced self-renewal activity, tumorigenic potential and IR resistance compared to CXCR4- cells. (a) MTT assay, (b) sphere-forming assay (white bar 50 mm), (c) limiting dilution assay, (d) soft agar assay (white bar 50 μm), (e) IR cl, 22onogenic survival assay (black bar 50 mm), and (f) Western blot (left) and RT-PCR (right) analyses of DTC cells after sorting with apc-conjugated CXCR4 antibody. *p < .05. All experimental results were obtained from at least three independent experiments.
Techniques Used: Activity Assay, MTT Assay, Limiting Dilution Assay, Soft Agar Assay, Clonogenic Cell Survival Assay, Western Blot, Reverse Transcription Polymerase Chain Reaction
Figure Legend Snippet: Figure 2. Silencing of CXCR4 via shRNA infection suppresses self-renewal activity, tumorigenic potential and IR resistance in DTC cells. (a) MTT assay, (b) sphere-forming assay (white bar 50 mm), (c) limiting dilution assay, (d) soft agar assay (white bar 50 μm), (e) IR clonogenic survival assay (black bar 50 mm), (f) Western blot (left) and RT-PCR (right), and (g) immunofluorescence (white bar 100 μm) analyses of DTC cells infected with shControl (shCTL), shCXCR4 a or D (upper) and quantification of the results (lower). *p < .05, **p < .01, ***p < .001. All experimental results were obtained from at least three independent experiments.
Techniques Used: shRNA, Infection, Activity Assay, MTT Assay, Limiting Dilution Assay, Soft Agar Assay, Clonogenic Cell Survival Assay, Western Blot, Reverse Transcription Polymerase Chain Reaction, Immunofluorescence
Figure Legend Snippet: Figure 5. CXCR4 overexpressing U-CH1 cells exhibited higher self-renewal activity, tumorigenic potential and IR resistance than control cells. (a) MTT assay, (b) sphere- forming assay (white bar 50 mm), (c) limiting dilution assay, (d) soft agar assay (white bar 50 μm), (e) IR clonogenic survival assay (black bar 50 mm), (f) Western blot (left) and RT-PCR (right), and (g) immunofluorescence (white bar 100 μm) analyses of DTC cells of transduced with control (pQCXIP) and CXCR4 carrying retroviruses in U-CH1 cells (upper) and quantification of the results (lower). *p < .05, **p < .01. All experimental results were obtained from at least three independent experiments.
Techniques Used: Activity Assay, Control, MTT Assay, Limiting Dilution Assay, Soft Agar Assay, Clonogenic Cell Survival Assay, Western Blot, Reverse Transcription Polymerase Chain Reaction, Immunofluorescence, Transduction
Figure Legend Snippet: Figure 6. Suppression of CXCR4 reduced tumorigenic potential and enhanced IR sensitivity of DTC cell in an in vivo xenograft model. (a) A representative image of tumor-bearing mice (left) and measurement of in vivo tumor growth rate (right) in shControl (shCTL) and shCXCR4-infected DTC cells subcutaneously transplanted in mice. (b) Combination therapy of IR and CXCR4 inhibitor (AMD3100, 5 mg/kg) in xenograft mouse model. (c) Immunohistochemistry (white bar 50 μm) of xenograft tissues probed with Sox2 antibody (left) and quantitation of the results (right) *p < .05, ***p < .001.
Techniques Used: In Vivo, Infection, Immunohistochemistry, Quantitation Assay
